JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
Why it matters
Attributed market update with source link for portfolio context.